Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 66

Type	Event	Organ system	Group	Affected	At risk
other	Colitis ulcerative	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	1	57
other	Colitis ulcerative	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	9	34
other	Haemorrhoids	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	1	57
other	Haemorrhoids	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	3	34
other	Pyrexia	General disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	2	57
other	Pyrexia	General disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	5	34
other	Nasopharyngitis	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	7	57
other	Nasopharyngitis	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	3	34
other	Arthralgia	Musculoskeletal and connective tissue disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	5	57
other	Arthralgia	Musculoskeletal and connective tissue disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Headache	Nervous system disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Headache	Nervous system disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	5	34
other	Eczema	Skin and subcutaneous tissue disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	2	57
other	Eczema	Skin and subcutaneous tissue disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Iron deficiency anaemia	Blood and lymphatic system disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Iron deficiency anaemia	Blood and lymphatic system disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Abdominal pain	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	1	57
other	Abdominal pain	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Anorectal discomfort	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Anorectal discomfort	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03648541/events

API reference For AI assistants

Adverse events66

Sources 3

Read this list from software.